Valbiotis
Develops clinically proven, plant-based supplements for metabolic diseases.
ALVAL | PA
Overview
Corporate Details
- ISIN(s):
- FR0013254851
- LEI:
- 969500VP4JBJCF0MOP60
- Country:
- France
- Address:
- RUE PAUL VATINE, 17180 PERIGNY
- Website:
- https://www.valbiotis.com/en/
- Sector:
- Manufacturing
- Industry:
- Manufacture of other food products
Description
Valbiotis is a research and development company that develops and commercializes plant-based dietary supplements for the prevention and management of metabolic diseases. The company's portfolio is centered on its patented "TOTUM" line of active substances, which undergo rigorous clinical trials to validate their efficacy. Key products include TOTUM•63 for reducing blood glucose in prediabetic individuals, TOTUM•448 for cardio-liver health, and TOTUM•854 for managing blood pressure. Valbiotis provides scientifically proven, natural, non-drug solutions and is transitioning from a research-focused model to a commercial-stage enterprise.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-09-06 07:35 |
Informations privilégiées / Autres communiqués
|
French | 895.3 KB | ||
| 2022-07-28 07:35 |
Valbiotis annonce avoir achevé le recrutement de l’étude clinique de Phase II/I…
|
French | 901.5 KB | ||
| 2022-07-28 07:35 |
Valbiotis announces completion of recruitment for the Phase II/III REVERSE-IT c…
|
English | 902.5 KB | ||
| 2022-07-25 17:40 |
Acquisition ou cession des actions de l'émetteur / Information relative au cont…
|
French | 186.5 KB | ||
| 2022-06-13 18:30 |
Inside Information / Other news releases
|
English | 940.3 KB | ||
| 2022-06-13 18:30 |
Valbiotis annonce le large succès de l’étude clinique de Phase II HEART : TOTUM…
|
French | 933.5 KB | ||
| 2022-05-19 17:40 |
Terms of availability of a registration document or its updates
|
English | 891.2 KB | ||
| 2022-05-19 17:40 |
Modalités de mise à disposition de document de référence ou de ses actualisatio…
|
French | 899.9 KB | ||
| 2022-05-06 17:40 |
Inside Information / Other news releases
|
English | 873.1 KB | ||
| 2022-05-06 17:40 |
Informations privilégiées / Autres communiqués
|
French | 873.5 KB | ||
| 2022-04-28 17:40 |
Inside Information / Other news releases
|
English | 911.0 KB | ||
| 2022-04-28 17:40 |
Valbiotis annonce la première visite du premier patient dans l'étude clinique d…
|
French | 901.9 KB | ||
| 2022-04-19 17:40 |
Terms of availability of the preparatory documents for the GM
|
English | 7.1 MB | ||
| 2022-04-19 17:40 |
Modalités de mise à disposition des documents préparatoires à l'AG
|
French | 7.1 MB | ||
| 2022-03-29 07:35 |
Inside Information / Other news releases
|
English | 706.0 KB |
Automate Your Workflow. Get a real-time feed of all Valbiotis filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Valbiotis
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Valbiotis via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-01-17 | N/A | Other | Other | 10,400 | 46,072.00 EUR |
Peer Companies
